CA3122636A1 - Insulin analogs having reduced insulin receptor binding affinity - Google Patents

Insulin analogs having reduced insulin receptor binding affinity Download PDF

Info

Publication number
CA3122636A1
CA3122636A1 CA3122636A CA3122636A CA3122636A1 CA 3122636 A1 CA3122636 A1 CA 3122636A1 CA 3122636 A CA3122636 A CA 3122636A CA 3122636 A CA3122636 A CA 3122636A CA 3122636 A1 CA3122636 A1 CA 3122636A1
Authority
CA
Canada
Prior art keywords
insulin
glu
val
des
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122636A
Other languages
English (en)
French (fr)
Inventor
Thomas Boehme
Stefan Guessregen
Marcus Hermann Korn
Martin Will
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68806785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3122636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3122636A1 publication Critical patent/CA3122636A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3122636A 2018-12-11 2019-12-10 Insulin analogs having reduced insulin receptor binding affinity Pending CA3122636A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18306657.0 2018-12-11
EP18306659 2018-12-11
EP18306659.6 2018-12-11
EP18306657 2018-12-11
EP18306658 2018-12-11
EP18306658.8 2018-12-11
PCT/EP2019/084427 WO2020120477A1 (en) 2018-12-11 2019-12-10 Insulin analogs having reduced insulin receptor binding affinity

Publications (1)

Publication Number Publication Date
CA3122636A1 true CA3122636A1 (en) 2020-06-18

Family

ID=68806785

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3122636A Pending CA3122636A1 (en) 2018-12-11 2019-12-10 Insulin analogs having reduced insulin receptor binding affinity
CA3122637A Pending CA3122637A1 (en) 2018-12-11 2019-12-10 Peptide binder
CA3122632A Pending CA3122632A1 (en) 2018-12-11 2019-12-10 Insulin conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3122637A Pending CA3122637A1 (en) 2018-12-11 2019-12-10 Peptide binder
CA3122632A Pending CA3122632A1 (en) 2018-12-11 2019-12-10 Insulin conjugates

Country Status (15)

Country Link
US (3) US11098102B2 (cg-RX-API-DMAC7.html)
EP (3) EP3894435A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022513776A (cg-RX-API-DMAC7.html)
KR (3) KR20210102347A (cg-RX-API-DMAC7.html)
CN (3) CN113396157A (cg-RX-API-DMAC7.html)
AU (3) AU2019398658A1 (cg-RX-API-DMAC7.html)
BR (3) BR112021011050A2 (cg-RX-API-DMAC7.html)
CA (3) CA3122636A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007453A2 (cg-RX-API-DMAC7.html)
IL (3) IL283800A (cg-RX-API-DMAC7.html)
MX (3) MX2021006972A (cg-RX-API-DMAC7.html)
PH (1) PH12021551339A1 (cg-RX-API-DMAC7.html)
SG (3) SG11202106166TA (cg-RX-API-DMAC7.html)
TW (3) TW202039437A (cg-RX-API-DMAC7.html)
WO (3) WO2020120477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
CN112876388B (zh) * 2021-01-14 2023-03-31 山东大学 一种gpr120激动剂及其制备方法与应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114230451A (zh) * 2021-12-29 2022-03-25 上海药坦药物研究开发有限公司 卤代酸类化合物的制备方法
US20250082758A1 (en) * 2022-01-26 2025-03-13 Sanofi Insulin conjugates
JP2025522529A (ja) 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのFc結合体
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用
CN118063589A (zh) * 2024-02-04 2024-05-24 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
ATE513921T1 (de) 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP1974729A1 (en) * 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2262539B1 (en) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin albumin conjugates
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
EP2376531A1 (en) 2008-12-09 2011-10-19 Novo Nordisk A/S Novel insulin analogues
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン類似体
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
AU2011252127B2 (en) 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー/エス 新規n末端修飾インスリン誘導体
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
EP2771026A4 (en) * 2011-10-27 2015-08-05 Univ Case Western Reserve ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS
CN104011070A (zh) 2011-12-15 2014-08-27 爱德迪安(北京)生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
MX2015005662A (es) 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
KR20140106452A (ko) 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン‐インクレチン複合物
US20160296602A1 (en) 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
WO2015016293A1 (ja) * 2013-08-02 2015-02-05 国立大学法人 富山大学 (ベンゼンスルホニルアミノ)ベンズアミド誘導体およびそれらを有効成分とするship2阻害剤
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
WO2016001185A1 (en) 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
JP6737793B2 (ja) 2015-01-29 2020-08-12 ノヴォ ノルディスク アー/エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
WO2017032599A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S A medical injection device with a cleaning chamber
CN108368163A (zh) 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
PL239062B1 (pl) 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
AU2017361524B2 (en) 2016-11-21 2022-06-02 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
EP3939605A1 (en) * 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
EP3578204A4 (en) 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. CONJUGATE MADE FROM BIOACTIVE MATERIAL WITH INCREASED RESISTANCE AND USE OF IT
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
KR20220112817A (ko) 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법

Also Published As

Publication number Publication date
AU2019398658A1 (en) 2021-07-29
JP2022513776A (ja) 2022-02-09
TW202039539A (zh) 2020-11-01
WO2020120463A1 (en) 2020-06-18
MX2021006969A (es) 2021-07-15
EP3894435A1 (en) 2021-10-20
CN113395982A (zh) 2021-09-14
BR112021011050A2 (pt) 2021-08-31
WO2020120479A1 (en) 2020-06-18
US12195510B2 (en) 2025-01-14
EP3894391A1 (en) 2021-10-20
CN113396157A (zh) 2021-09-14
KR20210102347A (ko) 2021-08-19
AU2019398579A1 (en) 2021-07-29
CA3122637A1 (en) 2020-06-18
JP2022511567A (ja) 2022-01-31
TW202039438A (zh) 2020-11-01
JP2022513775A (ja) 2022-02-09
IL283800A (en) 2021-07-29
US11098102B2 (en) 2021-08-24
KR20210102345A (ko) 2021-08-19
PH12021551339A1 (en) 2021-11-29
BR112021011156A2 (pt) 2021-10-26
EP3893934A1 (en) 2021-10-20
SG11202106166TA (en) 2021-07-29
MX2021006970A (es) 2021-07-15
CA3122632A1 (en) 2020-06-18
KR20210102346A (ko) 2021-08-19
US20220048968A1 (en) 2022-02-17
MX2021006972A (es) 2021-08-16
IL283801A (en) 2021-07-29
WO2020120477A1 (en) 2020-06-18
IL283803A (en) 2021-07-29
SG11202106167XA (en) 2021-07-29
TW202039437A (zh) 2020-11-01
US20200181223A1 (en) 2020-06-11
CO2021007453A2 (es) 2021-06-21
EP3893934B1 (en) 2025-09-10
SG11202106168VA (en) 2021-07-29
US20250206798A1 (en) 2025-06-26
BR112021011099A2 (pt) 2021-10-26
CN113423691A (zh) 2021-09-21
AU2019398402A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
KR20210102347A (ko) 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
JP5710253B2 (ja) 速効型インスリンアナログ
EP0891378B1 (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
RU2678134C2 (ru) Конъюгаты инсулин-инкретин
US20050014679A1 (en) Insulin molecule having protracted time action
KR20050121748A (ko) 연장된 시간 작용을 갖는 인슐린 유사체
KR20110061552A (ko) 할로겐 안정화된 인슐린
US20030104981A1 (en) Human insulin analogues
KR20170134542A (ko) 프로톡신-ii 변이체 및 사용 방법
KR20150138251A (ko) 부위 2 인슐린 유사체
US20230346949A1 (en) A method of forming a conjugate of a sulfonamide and a polypeptide
RS65822B1 (sr) Novi insulinski analozi i njihova upotreba
US20240043493A1 (en) Acylated single-chain insulin analogues
EP3888667B1 (en) Glucagon analog and methods of use thereof
RU2816595C2 (ru) Аналоги инсулина, характеризующиеся сниженной аффинностью связывания с рецепторами инсулина
JP2010535842A (ja) 速効型インスリンアナログ
RU2809189C2 (ru) Конъюгаты инсулина
HK1238651A1 (en) Biphasic single-chain insulin analogues
ZA200404273B (en) Insulin molecule having protracted time action.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260610